One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: Subgroup analyses from ULTRA 2

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 2, 2013, Pages 204-213

  Sandborn, W J ^a   Colombel, J F ^b   D'Haens, G ^c,d   Van Assche, G ^e,f   Wolf, D ^g   Kron, M ^h   Lazar, A ^h   Robinson, A M ⁱ   Yang, M ⁱ   Chao, J D ⁱ   Thakkar, R ⁱ  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d Imelda GI Clinical Research Center   (Belgium)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g Atlanta Gastroenterology Associates   (United States)

^h ABBOTT GMBH AND CO KG   (Germany)

ⁱ ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEALING; HEMATOLOGIC DISEASE; HUMAN; INDUCTION CHEMOTHERAPY; INJECTION SITE PAIN; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MAYO SCORE; MUCOSAL HEALING; MULTICENTER STUDY; NON MELANOMA SKIN CANCER; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK BENEFIT ANALYSIS; SCORING SYSTEM; TREATMENT FAILURE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872832486     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12145     Document Type: Article

References (21)

1. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ,. Ulcerative colitis. Lancet 2012; 380: 1606-19.
2. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology. Practice Parameters Committee. Am J Gastroenterol 2010; 105: 501-23.
3. Remicade [package insert]. Horsham, PA USA: Janssen Biotech, Inc., 2011.
4. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
5. Sandborn WJ, van Assche G, Reinisch W, et al,. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
6. Schroeder KW, Tremaine WJ, Ilstrup DM,. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-9.
7. Lewis JD, Chuai S, Nessel L, et al,. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-6.
8. Altman DG, Schulz KF, Moher D, et al,. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001; 134: 663-94.
9. Boada JN, Boada C, Garcia-Saiz M, et al,. Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance. PLoS ONE 2008; 3: e3580.
10. Whittle SL, Richards BL, Husni E, et al,. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev 2011; 11: CD003113.
11. Whittle SL, Richards BL, van der Heijde DM, et al,. The efficacy and safety of opioids in inflammatory arthritis: a cochrane systematic review. J Rheumatol Suppl 2012; 90: 40-6.
12. Travis SP, Stange EF, Lemann M, et al,. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62.
13. Bastida G, Nos P, Aguas M, et al,. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-82.
14. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
15. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al,. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011; 141: 1621-8.
16. Hueting WE, Buskens E, van der Tweel I, et al,. Results and complications after ileal pouch anal anastomosis: a meta-analysis of 43 observational studies comprising 9317 patients. Dig Surg 2005; 22: 69-79.
17. Kaplan GG, McCarthy EP, Ayanian JZ, et al,. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology 2008; 134: 680-7.
18. Navaneethan U, Venkatesh PGK, Shen B,. Risks and benefits of ileal pouch-anal anastomosis for ulcerative colitis. Therapy 2010; 8: 83-99.
19. Feagan B, Sandborn W, Yang M, et al,. Adalimumab therapy reduces hospitalization and colectomy rates in patients with ulcerative colitis: Data from controlled clinical trials. Stockholm, Sweden: United European Gastroenterology Week, 2011.
20. Burmester GR, Panaccione R, Gordon KB, et al,. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2012; doi: 10.1136/annrheumdis- 2011-201244 [Epub ahead of print].
21. Colombel JF, Sandborn WJ, Panaccione R, et al,. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1308-19.